<DOC>
	<DOC>NCT00871403</DOC>
	<brief_summary>The main purpose of this study is to determine whether the combination of pazopanib and pemetrexed is safe and effective in the treatment of advanced non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Written informed consent At least 18 years old Histologically or cytologicallyconfirmed diagnosis of predominantly nonsquamous cell Stage IIIBwet (with confirmed malignant pleural effusion) or Stage IV NSCLC No prior systemic firstline therapy for advanced NSCLC Measurable disease Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy of at least 12 weeks Able to swallow and retain oral medication Adequate organ system function (hematological, hepatic, and renal) Nonchildbearing potential (i.e., physiologically incapable of becoming pregnant) OR childbearing potential, and agrees to use adequate contraception. A male with a female partner of childbearing potential is eligible if he uses a barrier method of contraception or abstinence during the study Active malignancy or any malignancy in the 3 years prior to first dose of study drug other than NSCLC Central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for asymptomatic, previously treated CNS metastases Clinically significant gastrointestinal abnormalities Prolongation of corrected QT interval (QTc) &gt; 480 msecs History of any one or more cardiovascular conditions within the past 6 months prior to randomization Poorly controlled hypertension History of cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months Major surgery or trauma within 28 days or any nonhealing wound, fracture, or ulcer Evidence of active bleeding or bleeding diathesis Recent hemoptysis Endobronchial lesions and/or lesions infiltrating major pulmonary vessels Serious and/or unstable preexisting medical (e.g., uncontrolled infection), psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures Use of any prohibited medication Use of an investigational agent within 28 days or 5 halflives, whichever is longer, prior to the first dose of study drug Ongoing toxicity from prior anticancer therapy that is &gt;Grade 1 and/or that is progressing in severity except alopecia Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib, pemetrexed, and/or cisplatin Inability to interrupt aspirin or other nonsteroidal antiinflammatory drugs during the study Inability or unwillingness to take folic acid, vitamin B12 supplementation, or dexamethasone Clinically significant thirdspace fluid collections (e.g., ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study start Recent or concurrent yellow fever vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>GW786034</keyword>
	<keyword>pazopanib</keyword>
	<keyword>pemetrexed</keyword>
	<keyword>cisplatin</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>